上海之江生物科技股份有限公司 关于开展外汇衍生品交易业务的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海之江生物科技股份有限公司（以下简称"公司"）为有效防范并降 低外汇市场波动风险，以降低汇率大幅波动可能对公司经营业绩带来的影响，公 司及合并范围内的子公司拟开展外汇衍生品交易业务,预计交易额度不超过 2,000 万美元（或等值其他货币）。交易业务主要包括但不限于：外汇远期、外 汇掉期、外汇期权、结构性远期及其他外汇衍生品产品业务。公司及合并范围内 的子公司拟开展外汇衍生品交易业务的交易对手为经监管机构批准、具有外汇衍 生品业务经营资质且经营稳健、资信良好的境内大型银行等金融机构。上述交易 额度自 2025 年第二次临时股东会通过之日起 12 个月内有效，有效期内可以滚动 使用。 已履行的审议程序：公司于 2025 年 10 月 28 日召开第五届董事会第十七 次会议，审议通过了《关于开展外汇衍生品交易业务的议案》，该议案尚需提交 公司 2025 年第二次临时股东会审议。 特别风险提示：公司拟开展 ...

证券代码：688317 证券简称：之江生物 公告编号：2025-061 上海之江生物科技股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 14 日 14 点 00 分 召开地点：上海市闵行区陈行路 2388 号 8 幢 102 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 不涉及 二、 会议审议事项 本次股东会审议议案及投票股东类型 网络投票起止时间：自2025 年 11 月 14 日 至2025 年 11 月 14 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30 ...

Core Viewpoint - Zhijiang Biology (688317.SH) reported a significant decline in revenue and net profit for Q3 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for Q3 2025 was 30.75 million yuan, representing a year-on-year decrease of 28.46% [1] - The net profit attributable to shareholders of the listed company was -19.53 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -24.00 million yuan [1]

Financial Performance - The company's operating revenue for the third quarter was ¥30,749,789.88, a decrease of 28.46% compared to the same period last year[3]. - The total profit for the third quarter was a loss of ¥18,338,008.92, with a year-to-date loss of ¥25,938,257.20[3]. - The net profit attributable to shareholders for the third quarter was a loss of ¥19,526,883.18, and the year-to-date loss was ¥29,377,855.95[3]. - The company experienced a 34.27% decline in operating revenue year-to-date, primarily due to decreased product sales and price reductions from centralized procurement policies[8]. - Total operating revenue for the first three quarters of 2025 was ¥90,432,870.13, a decrease of 34.2% compared to ¥137,579,847.20 in the same period of 2024[18]. - Net profit for the first three quarters of 2025 was a loss of ¥29,377,855.95, compared to a loss of ¥13,009,588.94 in 2024, representing a deterioration of 126.5%[19]. Research and Development - Research and development expenses totaled ¥12,727,608.42 for the quarter, accounting for 41.39% of operating revenue, an increase of 7.25 percentage points year-on-year[4]. - Research and development expenses for the first three quarters of 2025 were ¥42,058,199.29, an increase of 7.6% from ¥39,074,589.30 in 2024[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,721,101,815.28, a decrease of 1.82% from the end of the previous year[4]. - The total amount of current assets as of September 30, 2025, is approximately ¥2.94 billion, slightly increased from ¥2.93 billion in the previous year[14]. - Total assets amount to ¥3.72 billion, down from ¥3.79 billion in the previous year[14]. - Non-current assets total ¥783.24 million, a decrease from ¥854.34 million year-over-year[14]. - The total liabilities increased to ¥327,172,042.30 in 2025, compared to ¥153,063,328.61 in 2024, indicating a significant rise[16]. - The total equity attributable to shareholders decreased to ¥3,393,929,772.98 in 2025 from ¥3,636,886,762.51 in 2024, a decline of 6.7%[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥32,672,416.67, a decrease of 23.89% compared to the previous year[3]. - Cash inflow from operating activities totaled ¥172,091,272.35 in 2025, down 29.3% from ¥243,668,973.36 in 2024[22]. - The cash flow from sales of goods and services was ¥120,213,144.22 in 2025, down 24% from ¥158,023,714.74 in 2024[22]. - The net cash flow from operating activities was $32,672,416.67, a decrease of 24% compared to $42,926,358.23 in the previous period[23]. - The total cash outflow from operating activities was $139,418,855.68, compared to $200,742,615.13 previously, showing a reduction in operational cash outflows[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 14,435[11]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, representing 33.81% of total shares[11]. - The company has a total of 14,638,308 shares in its repurchase account, accounting for 7.62% of total shares[13]. - The company has no significant changes in the participation of major shareholders in margin trading or securities lending[13]. Other Financial Metrics - The weighted average return on net assets was -0.56%, an increase of 0.47 percentage points compared to the previous year[4]. - The basic earnings per share for the third quarter was -¥0.10, with a year-to-date figure of -¥0.16[4]. - The company reported non-recurring gains and losses totaling ¥4,477,565.75 for the quarter[7]. - The company reported a financial expense of -¥31,340,122.83 in 2025, a significant improvement from -¥67,266,345.27 in 2024[18]. - The company recorded a credit impairment loss of ¥1,168,467.86 in 2025, compared to a recovery of -¥215,377.15 in 2024[19]. - The company paid $57,114,359.51 in employee compensation, which is lower than $78,188,799.34 in the previous period[23]. - The company experienced a foreign exchange loss of -$9,676,055.88, compared to -$10,932,424.75 in the prior period[23]. - The company has not disclosed any new strategies or future outlook in the provided documents[12].

Core Insights - The company reported a third-quarter revenue of 30.75 million yuan, representing a year-on-year decline of 28.46% [1] - The net profit for the third quarter was a loss of 19.53 million yuan [1] - For the first three quarters, the total revenue was 90.43 million yuan, down 34.27% year-on-year [1] - The net profit for the first three quarters was a loss of 29.38 million yuan [1]

关于 2025 年第三次以集中竞价交易方式回购股份的回 购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2025-058 重要内容提示： 上海之江生物科技股份有限公司（以下简称"公司"）拟通过集中竞价交易方 式回购部分公司已发行的普通股（A 股）股份，主要内容如下： ● 回购股份金额：不低于人民币 6,000 万元（含），不超过人民币 12,000 万 元（含）。 上海之江生物科技股份有限公司 ● 回购股份资金来源：公司自有资金和股票回购专项贷款资金。公司已取得 北京银行股份有限公司上海分行出具的《贷款承诺函》，具体贷款事宜将以双方签 订的贷款合同为准。 ● 回购股份用途：回购的股份拟用于员工持股计划或股权激励。 ● 回购股份价格：不超过人民币 37.99 元/股（含），该价格不高于公司董事 会通过回购决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自公司董事会审议通过本次回购方案之日起 12 个月 ...

上海之江生物科技股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688317 证券简称：之江生物 公告编号：2025-057 二、前十名无限售条件股东持股情况 | 序号 | 股东名称 | 持股数量（股） | 持股比例（%） | | --- | --- | --- | --- | | 1 | 上海之江药业有限公司 | 64,969,560 | 33.81 | | 2 | 上海之江生物科技股份有限公司 | 14,638,308 | 7.62 | | | 回购专用证券账户 | | | | 3 | 宁波康飞顿斯投资管理合伙企业 （有限合伙） | 6,002,000 | 3.12 | | 4 | 招商银行股份有限公司－广发价 值核心混合型证券投资基金 | 4,803,416 | 2.50 | | 5 | 宁波睿道创业投资合伙企业（有 | 2,995,199 | 1.56 | | | 限合伙） | | | | 6 | 中国银行股份有限公司－广发医 ...

Core Points - The company reported a significant decline in revenue and net profit for the first half of 2025, with a revenue of 59.68 million yuan, down 36.91% year-on-year, and a net profit attributable to shareholders of -9.85 million yuan [1] - The company has projected net losses of 137 million yuan and 127 million yuan for the years 2023 and 2024, respectively [2] Financial Performance - In the first half of 2025, the company achieved a net cash flow from operating activities of 25.82 million yuan [1] - The net profit after deducting non-recurring gains and losses for the first half of 2025 was -13.25 million yuan [1] IPO and Stock Performance - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2021, with an initial issuance of 48,676,088 shares at a price of 43.22 yuan per share [3] - The stock price peaked at 93.80 yuan within six trading days after the IPO but has since experienced a downward trend, currently trading below the IPO price [3] - The total funds raised during the IPO amounted to 2.10 billion yuan, with a net amount of 1.94 billion yuan, exceeding the original plan by 586.43 million yuan [3] Use of IPO Proceeds - The funds raised are intended for projects including the upgrade of production lines, the establishment of a molecular diagnostics research center, marketing and service network upgrades, product development, and to supplement working capital [4]

Group 1 - Junshi Biosciences' JS207 received FDA approval for a Phase II/III clinical trial targeting neoadjuvant treatment in resectable, driver gene-negative non-small cell lung cancer patients, enhancing its international expansion and market potential [1] Group 2 - Eli Lilly's oral GLP-1 drug orforglipron demonstrated significant efficacy in two Phase III trials, achieving primary and all key secondary endpoints, including notable reductions in HbA1c, weight loss, and improvements in cardiovascular risk factors, reinforcing its competitive position in the GLP-1 market [2] Group 3 - Guobang Pharmaceutical reported a 23.17% year-on-year increase in net profit for Q3, despite a 5.39% decline in revenue, attributed to improved sales collection and optimized procurement payments, showcasing strong profitability resilience [3] Group 4 - Zhijiang Biopharmaceutical announced a share buyback plan of 60 million to 120 million yuan to support employee stock ownership plans or equity incentives, reflecting confidence in long-term development and aiming to strengthen core team commitment [4]

Core Viewpoint - Shanghai Zhijiang Biological Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total amount between RMB 60 million and RMB 120 million, aimed at employee stock ownership plans or equity incentives [2][3][31] Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 60 million and not exceed RMB 120 million [2][17] - The funding sources for the repurchase will be the company's own funds and special loan funds for stock repurchase, with a loan commitment letter obtained from Beijing Bank [2][19] - The repurchase price will not exceed RMB 37.99 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][18] - The repurchase will be conducted through centralized bidding [4][11] - The repurchase period is set for 12 months from the board's approval date [5][12] Purpose and Use of Repurchased Shares - The repurchased shares are intended for employee stock ownership plans or equity incentives, promoting a long-term incentive mechanism [9][31] - If the shares are not transferred within three years after the repurchase, the company will reduce its registered capital accordingly [23][31] Board Meeting and Approval - The board meeting to approve the repurchase plan was held on October 15, 2025, with unanimous approval from all attending directors [7][29] - The repurchase plan does not require shareholder meeting approval as per relevant regulations [8][31] Financial Impact and Structure - As of June 30, 2025, the company's total assets were approximately RMB 3.78 billion, and the net assets attributable to shareholders were about RMB 3.45 billion [20][21] - The repurchase funds will account for approximately 3.18% of total assets and 3.48% of net assets, indicating a manageable impact on the company's financials [20][21] Shareholder and Management Plans - Major shareholders and management have no plans to reduce their holdings in the next three to six months [5][22][31] - The company will comply with legal obligations for information disclosure if any changes occur in shareholding plans [22][31]